CA2472340A1 - Process for the manufacture of organic compounds - Google Patents

Process for the manufacture of organic compounds Download PDF

Info

Publication number
CA2472340A1
CA2472340A1 CA002472340A CA2472340A CA2472340A1 CA 2472340 A1 CA2472340 A1 CA 2472340A1 CA 002472340 A CA002472340 A CA 002472340A CA 2472340 A CA2472340 A CA 2472340A CA 2472340 A1 CA2472340 A1 CA 2472340A1
Authority
CA
Canada
Prior art keywords
formula
follows
independently
hydroxy
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002472340A
Other languages
English (en)
French (fr)
Inventor
Guang-Pei Chen
Prasad Koteswara Kapa
Eric M. Loeser
Ulrich Beutler
Werner Zaugg
Michael J. Girgis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2472340A1 publication Critical patent/CA2472340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Cephalosporin Compounds (AREA)
CA002472340A 2002-01-28 2003-01-27 Process for the manufacture of organic compounds Abandoned CA2472340A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35231602P 2002-01-28 2002-01-28
US60/352,316 2002-01-28
US38318802P 2002-05-24 2002-05-24
US60/383,188 2002-05-24
PCT/EP2003/000804 WO2003064382A2 (en) 2002-01-28 2003-01-27 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
CA2472340A1 true CA2472340A1 (en) 2003-08-07

Family

ID=27669055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002472340A Abandoned CA2472340A1 (en) 2002-01-28 2003-01-27 Process for the manufacture of organic compounds

Country Status (19)

Country Link
US (3) US6835838B2 (enExample)
EP (1) EP1472227B1 (enExample)
JP (1) JP2005516064A (enExample)
KR (2) KR20100091267A (enExample)
CN (2) CN1625550A (enExample)
AU (4) AU2003239294B2 (enExample)
BR (1) BR0307236A (enExample)
CA (1) CA2472340A1 (enExample)
CO (1) CO5601045A2 (enExample)
EC (1) ECSP045202A (enExample)
IL (1) IL162817A0 (enExample)
MX (1) MXPA04007308A (enExample)
NO (1) NO327363B1 (enExample)
NZ (3) NZ554366A (enExample)
PL (1) PL371383A1 (enExample)
RU (1) RU2360903C2 (enExample)
SG (2) SG161742A1 (enExample)
WO (1) WO2003064382A2 (enExample)
ZA (1) ZA200405239B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
PT1466905E (pt) 2001-11-14 2011-07-14 Nissan Chemical Ind Ltd Processo para a produção de éster do ácido oxo-heptenóico opticamente activo
DE60326819D1 (de) * 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
EP1539698B1 (en) * 2002-09-20 2010-10-20 Nissan Chemical Industries, Ltd. Method for producing a 3,5-dihydroxy-6-heptenoate
EP3299359A1 (en) 2003-02-12 2018-03-28 Nissan Chemical Industries, Ltd. Crystalline and amorphous forms of pitavastatin hemicalcium salt
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
CN1763015B (zh) * 2004-10-22 2011-06-22 四川抗菌素工业研究所有限公司 一种罗舒伐他汀及其药用盐的制备方法及中间体
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
SI2086945T1 (sl) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2010089770A2 (en) * 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
RU2425034C1 (ru) * 2010-01-11 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения производных (e)-4-(6,7-диметокси-2-метил-3-хинолил)-3-бутен-2-она
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
US9034901B2 (en) 2010-08-25 2015-05-19 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP2638013A4 (en) * 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
WO2012140490A2 (en) 2011-04-11 2012-10-18 Aurobindo Pharma Limited Process for preparing quinoline derivative
CN103755568B (zh) * 2013-12-10 2015-10-28 江西科技师范大学 IeodomycinA和B立体选择性合成方法
JP6704916B2 (ja) 2015-08-05 2020-06-03 株式会社エーピーアイ コーポレーション ピタバスタチンカルシウムの製造方法
CN108976168B (zh) * 2017-06-02 2020-09-25 浙江京新药业股份有限公司 一种匹伐他汀半钙盐晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JP3554036B2 (ja) * 1994-09-06 2004-08-11 宇部興産株式会社 光学活性な7−置換キノリル−3,5−ジヒドロキシ−ヘプト−6−エン酸エステル誘導体の製造方法
PT1466905E (pt) * 2001-11-14 2011-07-14 Nissan Chemical Ind Ltd Processo para a produção de éster do ácido oxo-heptenóico opticamente activo
EP2125754B1 (en) * 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium

Also Published As

Publication number Publication date
JP2005516064A (ja) 2005-06-02
CN100378081C (zh) 2008-04-02
US20030208072A1 (en) 2003-11-06
RU2004126448A (ru) 2005-06-27
KR20100091267A (ko) 2010-08-18
PL371383A1 (en) 2005-06-13
CN1625550A (zh) 2005-06-08
NO20043586L (no) 2004-10-07
BR0307236A (pt) 2004-12-07
EP1472227A2 (en) 2004-11-03
SG157225A1 (en) 2009-12-29
NO327363B1 (no) 2009-06-15
AU2006225205A1 (en) 2006-10-26
NZ554367A (en) 2008-11-28
US7572917B2 (en) 2009-08-11
US20040249154A1 (en) 2004-12-09
RU2360903C2 (ru) 2009-07-10
MXPA04007308A (es) 2004-10-29
NZ534136A (en) 2007-08-31
ZA200405239B (en) 2005-07-27
US20090299065A1 (en) 2009-12-03
AU2009208129A1 (en) 2009-09-03
AU2006225206B2 (en) 2009-08-06
CN1660818A (zh) 2005-08-31
NZ554366A (en) 2008-11-28
IL162817A0 (en) 2005-11-20
CO5601045A2 (es) 2006-01-31
AU2003239294B2 (en) 2006-10-19
KR20040077883A (ko) 2004-09-07
EP1472227B1 (en) 2016-04-27
SG161742A1 (en) 2010-06-29
WO2003064382A2 (en) 2003-08-07
US6835838B2 (en) 2004-12-28
AU2006225205B2 (en) 2009-08-06
ECSP045202A (es) 2004-09-28
AU2006225206A1 (en) 2006-10-26
WO2003064382A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
AU2003239294B2 (en) Process for the manufacture of organic compounds
AU2003239294A1 (en) Process for the manufacture of organic compounds
CN103025727B (zh) HMG-CoA还原酶抑制剂及其中间体的制备方法
CA2472776C (en) Process for the manufacture of hmg-coa reductase inhibitors
AU2003226971A1 (en) Process for the manufacture of HMG-CoA reductase inhibitors
CA2407862A1 (en) Process for the preparation of indole derivatives and intermediates of the process
WO2006021974A1 (en) A process for synthesizing diol (viii)-an intermediate of montelukast sodium
JP2007538041A (ja) ジフェニルアゼチジノン誘導体の製造方法
JP5150501B2 (ja) HMG−CoA還元酵素阻害薬を合成する方法
JPH0142946B2 (enExample)
HK1070651B (en) Process for the manufacture of hmg-coa reductase inhibitors
JPH0220637B2 (enExample)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued